Rep. Robert Bresnahan, Jr. Sells HCA Healthcare, Inc. (NYSE:HCA) Shares

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of HCA Healthcare, Inc. (NYSE:HCA). In a filing disclosed on March 27th, the Representative disclosed that they had sold between $1,001 and $15,000 in HCA Healthcare stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

HCA Healthcare Trading Down 0.0 %

Shares of HCA stock traded down $0.09 during mid-day trading on Friday, reaching $342.25. The company’s stock had a trading volume of 1,114,475 shares, compared to its average volume of 1,345,910. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $417.14. The firm has a market capitalization of $84.26 billion, a PE ratio of 15.58, a price-to-earnings-growth ratio of 1.10 and a beta of 1.68. The company has a quick ratio of 0.97, a current ratio of 1.08 and a debt-to-equity ratio of 69.07. The company’s 50 day simple moving average is $324.53 and its 200-day simple moving average is $341.56.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same period in the previous year, the firm posted $5.90 earnings per share. On average, research analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 17th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.84%. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.66. HCA Healthcare’s payout ratio is presently 13.11%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Norges Bank bought a new position in shares of HCA Healthcare in the fourth quarter valued at approximately $840,286,000. FMR LLC boosted its position in shares of HCA Healthcare by 322.3% during the 3rd quarter. FMR LLC now owns 3,141,769 shares of the company’s stock valued at $1,276,909,000 after purchasing an additional 2,397,883 shares in the last quarter. Royal London Asset Management Ltd. lifted its position in shares of HCA Healthcare by 62.0% during the 4th quarter. Royal London Asset Management Ltd. now owns 1,500,786 shares of the company’s stock valued at $450,461,000 after acquiring an additional 574,239 shares during the last quarter. Barclays PLC boosted its position in shares of HCA Healthcare by 85.7% in the 4th quarter. Barclays PLC now owns 1,061,891 shares of the company’s stock valued at $318,727,000 after purchasing an additional 489,916 shares during the period. Finally, Principal Financial Group Inc. increased its position in shares of HCA Healthcare by 120.1% in the fourth quarter. Principal Financial Group Inc. now owns 873,775 shares of the company’s stock worth $262,264,000 after acquiring an additional 476,756 shares in the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on HCA. Barclays lowered their target price on HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 target price on shares of HCA Healthcare in a research note on Monday, January 27th. Royal Bank of Canada reduced their price objective on shares of HCA Healthcare from $405.00 to $384.00 and set an “outperform” rating on the stock in a research note on Monday, January 27th. Truist Financial reduced their price target on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Finally, KeyCorp cut their price objective on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, HCA Healthcare currently has a consensus rating of “Moderate Buy” and an average target price of $385.67.

Insider Buying and Selling at HCA Healthcare

In related news, SVP Jennifer Berres sold 9,533 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the completion of the sale, the senior vice president now directly owns 15,412 shares in the company, valued at approximately $4,971,757.08. This trade represents a 38.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.30% of the company’s stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.